Genentech: Jim Kiefer | Senior Director Of SB NMR & Xray, Structural Biology

Scientists / Our Scientists

"Cancer and autoimmune diseases are prevalent among my family and friends. I am here, because I would like to fight back."

Years at Genentech

Publications at Genentech

My path to Genentech began in the Midwest, working at Searle, Pharmacia, and Pfizer for 12 years, in structure based drug design. Looking from the outside in, I had always been struck by how Genentech was consistently leading, rather than following, in the discovery of new medicines. I have been even more impressed by the culture and innovation here since joining in 2012.

I am structural biologist, but I think of myself as a “molecular photographer.” We determine the shapes of proteins bound to chemicals on the path to potentially becoming drugs and try to improve that interaction. The technique has broad applications from traditional, “small molecule” drugs to protein therapeutics. My primary interests involve pathways triggering cancer and inflammation.

SUMMARY OF PUBLICATIONS (PDF)

Featured Publication

A minor structural change to tertiary sulfonamide RORc ligands led to agonist and inverse agonist mechanisms of action.

ACS Med Chem Lett 6(3):276-281, 2015.

René O, Fauber BP, de Leon Boenig G, Burton B, Eidenschenk C, Everett C, Gobbi A, Hymowitz SG, Johnson AR, Kiefer JR, Liimatta M, Lockey P, Norman M, Ouyang W, Wallweber HA, Wong H.

View Abstract

My role at Genentech has encompassed three different facets. I have been the project leader for a target in the small molecule inflammation portfolio; I provide structures and analysis of them to teams, and I manage one arm of the Structural Biology Department. One of the aspects that I enjoy most about my position at Genentech is the diversity of experiences in my work each week.

I have primarily worked in areas relating to cancer and immunology and was part of the Joint Project Team in Genentech’s and Constellation Pharmaceuticals’ collaboration on Epigenetics research. I have a long-term interest in DNA replication and repair and gene regulation.

Discovery of GNE-502 as an orally bioavailable and potent degrader for estrogen receptor positive breast cancer

Bioorganic and Medicinal Chemistry Letters, ISSN: 14643405 0960894X

Jason R. Zbieg; Jun Liang; Jun Li; Robert A. Blake; Jae Chang; Lori S. Friedman; Simon Goodacre; Steven J. Hartman; Ellen Rei Ingalla; James R. Kiefer; Tracy L. Kleinheinz; Sharada Labadie; Tommy Lai; Jiangpeng Liao; Nev McLean; Ciara Metcalfe; Vidhi Mody; Michelle Nannini; Daniel F. Ortwine; Yingqing Ran; Nicholas C. Ray; Fabien Roussel; Amy Sambrone; Deepak Sampath; Maia Vinogradova; John Wai; Tao Wang; Kuen Yeap; Birong Zhang; Xiaoping Zheng; Yu Zhong; Xiaojing Wang

Attention: This page may not render properly. The browser you are using, Internet Explorer 10, is no longer supported.

We are actively responding to the global COVID-19 pandemic. For more, please visit our COVID-19 response page, or call 1-877-436-3683. See the latest update on Actemra® (tocilizumab) supply here.

Jim Kiefer

Senior Director Of SB NMR & Xray, Structural Biology

Featured Publication

A minor structural change to tertiary sulfonamide RORc ligands led to agonist and inverse agonist mechanisms of action.